期刊
NATURE REVIEWS ENDOCRINOLOGY
卷 16, 期 11, 页码 654-667出版社
NATURE RESEARCH
DOI: 10.1038/s41574-020-0386-0
关键词
-
资金
- Hong Kong Research Grants Council/Area of Excellence [AoE/M/707-18]
- Collaborative Research Fund [C7037-17W]
- General Research Fund [17125317, 17127518]
- Science and Technology Major Project of Hunan Province [2017SK1020]
Fibroblast growth factor 21 (FGF21) confers considerable pharmacological benefits on a cluster of obesity-related metabolic complications when administered to preclinical models. This Review discusses FGF21 analogues and mimetics and highlights their efficacy in preclinical models and clinical trials. The challenges in developing FGF21-based therapeutics are also considered. Fibroblast growth factor 21 (FGF21) is a stress-inducible hormone that has important roles in regulating energy balance and glucose and lipid homeostasis through a heterodimeric receptor complex comprising FGF receptor 1 (FGFR1) and beta-klotho. Administration of FGF21 to rodents or non-human primates causes considerable pharmacological benefits on a cluster of obesity-related metabolic complications, including a reduction in fat mass and alleviation of hyperglycaemia, insulin resistance, dyslipidaemia, cardiovascular disorders and non-alcoholic steatohepatitis (NASH). However, native FGF21 is unsuitable for clinical use owing to poor pharmacokinetic and biophysical properties. A large number of long-acting FGF21 analogues and agonistic monoclonal antibodies for the FGFR1-beta-klotho receptor complexes have been developed. Several FGF21 analogues and mimetics have progressed to early phases of clinical trials in patients with obesity, type 2 diabetes mellitus and NASH. In these trials, the primary end points of glycaemic control have not been met, whereas substantial improvements were observed in dyslipidaemia, hepatic fat fractions and serum markers of liver fibrosis in patients with NASH. The complexity and divergence in pharmacology and pathophysiology of FGF21, interspecies variations in FGF21 biology, the possible existence of obesity-related FGF21 resistance and endogenous FGF21 inactivation enzymes represent major obstacles to clinical implementation of FGF21-based pharmacotherapies for metabolic diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据